1. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus.
- Author
-
Viúdez A, Crespo G, Gómez Dorronsoro ML, Arozarena I, Marín-Méndez JJ, Custodio A, Benavent M, Goñi S, García-Paredes B, Hernando J, Durantez M, Alonso V, Riesco MDC, López C, Jiménez-Fonseca P, San Vicente BL, González-Borja I, Sevilla I, Hernández-Garcia I, Carmona-Bayonas A, Capdevila J, Pérez-Sanz J, García-Carbonero R, Pérez-Ricarte L, Llanos M, Vera R, and De Jesús Acosta A
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor analysis, Cell Cycle Proteins analysis, Cell Line, Tumor, DNA Modification Methylases analysis, DNA Repair Enzymes analysis, Female, Humans, Intracellular Signaling Peptides and Proteins analysis, Male, Middle Aged, Neoplasm Recurrence, Local, Neuroendocrine Tumors mortality, Nuclear Proteins analysis, Pancreatic Neoplasms mortality, Prognosis, Progression-Free Survival, Survival Analysis, Tumor Suppressor Proteins analysis, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Everolimus therapeutic use, Immunohistochemistry methods, Immunosuppressive Agents therapeutic use, Neuroendocrine Tumors drug therapy, Neuroendocrine Tumors pathology, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms pathology
- Abstract
Background: Pancreatic neuroendocrine tumors are rare neoplasms for which few predictive and/or prognostic biomarkers have been validated. Our previous work suggested the potential of the combined expression of N-myc downstream-regulated gen-1 (NDRG-1), O6-methylguanine DNA methyltransferase (MGMT) and Pleckstrin homology-like domain family A member 3 (PHLDA-3) as prognostic factors for relapse and survival., Methods: In this new multicenter study we evaluated immunohistochemistry expression in 76 patients with advanced PanNET who were treated with capecitabine-temozolomide or everolimus. Based on the immunohistochemistry panel, an immunohistochemistry prognostic score (IPS) was developed., Results: In patients treated with capecitabine and temozolomide, low IPS was an independent prognostic factor for progression-free-survival and overall-survival. Similar findings were observed with highest IPS for overall-survival in patients treated with everolimus., Conclusion: From our knowledge, it is the first time that a simple IPS could be useful to predict outcome for patients with metastatic pancreatic neuroendocrine tumors treated with everolimus or capecitabine and temozolomide., (Copyright © 2020 IAP and EPC. Published by Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF